SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales figure stood at Rs. 14183.08 millions for the December 2025 quarter. The mentioned figure indicates a growth of about 37.86% as compared to Rs. 10288.13 millions during the year-ago period.The Net Profit of the company vaulted to 415.60% to Rs. 2588.51  millions from Rs. 502.04 millions in the previous quarter.OP of the company witnessed a marginal growth to 4388.04 millions from 1438.27 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 14183.08 10288.13 37.86 37754.85 31037.36 21.64 43819.24 34976.55 25.28
Other Income 1383.00 194.10 612.52 2119.63 1022.86 107.23 1188.07 1262.36 -5.89
PBIDT 4388.04 1438.27 205.09 9356.72 4986.11 87.66 7656.44 5801.51 31.97
Interest 331.52 199.29 66.35 814.04 888.93 -8.42 1129.62 1660.92 -31.99
PBDT 3765.02 1238.98 203.88 8216.18 4097.18 100.53 6526.82 4047.44 61.26
Depreciation 621.37 566.46 9.69 1836.93 1680.60 9.30 2249.72 2048.32 9.83
PBT 3143.65 672.52 367.44 6379.25 2416.58 163.98 4277.10 1999.12 113.95
TAX 555.14 170.48 225.63 1386.63 640.87 116.37 1105.82 390.78 182.98
Deferred Tax -93.80 105.19 -189.17 -162.16 149.70 -208.32 -21.25 4.97 -527.57
PAT 2588.51 502.04 415.60 4992.62 1775.71 181.16 3171.28 1608.34 97.18
Equity 1895.73 1894.32 0.07 1895.73 1894.32 0.07 1894.83 1811.52 4.60
PBIDTM(%) 30.94 13.98 121.31 24.78 16.06 54.27 17.47 16.59 5.34

Emcure Pharma Share Price

1603.60 -26.50 (-1.63%)
21-Apr-2026 12:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1221.00
Cipla 1232.40
Zydus Lifesciences 929.55
Lupin 2322.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×